Premium
Serum cytochrome c to indicate the extent of ongoing tumor cell death
Author(s) -
OSAKA A.,
HASEGAWA H.,
TSURUDA K.,
INOKUCHI N.,
YANAGIHARA K.,
YAMADA Y.,
AOYAMA M.,
SAWADA T.,
KAMIHIRA S.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2008.01033.x
Subject(s) - apoptosis , biomarker , cytochrome c , carcinogenesis , lactate dehydrogenase , cancer research , in vivo , programmed cell death , biology , immunology , cancer , medicine , enzyme , biochemistry , microbiology and biotechnology
Summary Despite the significant implication of apoptosis in tumorigenesis, there is no biomarker to assess the extent of ongoing apoptosis in vivo for hematological malignancies. We investigated the potential of serum cytochrome c (cyto‐c) as a biomarker for apoptosis. Cyto‐c and lactate dehydrogenase (LD) were released into the culture medium from apoptotic cells induced by tumor necrosis factor‐related apoptosis‐inducing ligand in a time‐dependent manner in vitro , with different kinetic patterns. Only one‐third of 153 patients with hematological malignancies showed high levels of serum cyto‐c (>20 ng/ml). Although serum cyto‐c level was roughly correlated to serum LD activity, their different kinetic patterns from serial measurements indicated that serum cyto‐c rather than LD is a more sensitive indicator for tracking changes of tumor status. Furthermore, serum cyto‐c level stratified patients with acute adult T‐cell leukemia into favorable and unfavorable subgroups with 5‐year survival rates of 67% vs. 11%. In conclusion, serum cyto‐c may provide a fast real‐time biomarker for tracking changes of tumor status involved in apoptotic cell death, but lacking disease or cell‐type specificity.